|
|
||||||||
2-C
3 Amplification and the Ke+Oz- Polymorphism in the Human Ig
Locus
Department of Immunology, Erasmus University Rotterdam/University Hospital Rotterdam, Rotterdam, The Netherlands
Two polymorphisms of the human Ig
(IGL) locus
have been described. The first polymorphism concerns a single, 2- or
3-fold amplification of 5.4 kb of DNA in the C
2-C
3 region. The
second polymorphism is the
Mcg-Ke+Oz- isotype, which has
only been defined via serological analyses in Bence-Jones proteins of
multiple myeloma patients and was assumed to be encoded by a
polymorphic C
2 segment because of its high homology with the
Mcg-Ke-Oz- C
2 isotype. It has
been speculated that the
Mcg-Ke+Oz- isotype might be
encoded by a C
gene segment of the amplified C
2-C
3 region. We
now unraveled both IGL gene polymorphisms. The
amplification polymorphism appeared to result from a duplication,
triplication, or quadruplication of a functional J-C
2 region and is
likely to have originated from unequal crossing over of the J-C
2 and
J-C
3 region via a 2.2-kb homologous repeat. The amplification
polymorphism was found to result in the presence of one to five extra
functional J-C
2 per genome regions, leading to decreased Ig
:Ig
ratios on normal peripheral blood B cells. Via sequence analysis, we
demonstrated that the Mcg-Ke+Oz-
isotype is encoded by a polymorphic C
2 segment that differs from the
normal C
2 gene segment at a single nucleotide position. This
polymorphism was identified in only 1.5% (2 of 134) of individuals
without J-C
2 amplification polymorphism and was not found in the
J-C
2 amplification polymorphism of 44 individuals, indicating that
the two IGL gene polymorphisms are not
linked.
This article has been cited by other articles:
![]() |
J. A. L. Armour, R. Palla, P. L. J. M. Zeeuwen, M. d. Heijer, J. Schalkwijk, and E. J. Hollox Accurate, high-throughput typing of copy number variation using paralogue ratios from dispersed repeats Nucleic Acids Res., February 16, 2007; 35(3): e19 - e19. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |